ReviewGastroenterology clinics of North America2025
Dysbiotic Microbiota in Necrotizing Enterocolitis: Insights into Pathogenesis, Treatment, and Prevention.
Review in Gastroenterology clinics of North America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Observational
- Mechanisms by which tryptophan metabolites enhance intestinal barrier function to prevent necrotizing enterocolitis in preterm infants.Frontiers in immunology · 2026Review
- Risk factors and outcomes of infants with necrotizing enterocolitis: a case-control study.Frontiers in pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Necrotizing enterocolitis (NEC) is an inflammatory intestinal disease occurring primarily in infants born prematurely. The etiology is multifactorial and the clinical presentation is nonspecific. Due to the heterogeneity of disease and complexity of the physiology of preterm infants, decades of research have not yielded high-quality diagnostic or treatment strategies. This has translated into a failure to improve outcomes. Prevailing dogma supports a role for intestinal microbial dysbiosis in NEC pathogenesis, and as such, broad-spectrum antibiotics are central to treatment. The specific role of intestinal microbes and how modulation of the microbiome can influence disease remain an area of intensive research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.